Analysis of Neuropeptides by Mass Spectrometry

Technology #ua17-032

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Michael Heien
Associate Professor, Chemistry & Biochemistry
Managed By
Paul Eynott
Sr. Licensing Manager (520) 621-2878

Title: Analysis of Neuropeptides by Mass Spectrometry

 

Invention: This invention is an extraction method used to obtain samples of brain-derived neurotrophic factor (BDNF) and calcitonin gene related peptides (CGRP) that can be analyzed by high-resolution mass spectrometry.

 

Background: Neurotransmitters play a key role in a variety of neurological issues. Identifying those neurotransmitters and their concentrations provides insights about their onset as well as a method to diagnose them. In addition, peptide structural information can be used in drug development to simulate the actions of neurotransmitters.

 

Applications:

  • Drug Development: The information used from studying neuropeptides can be used to create more potent neurological drugs. The extractions methods can be used to expedite exiting neurological drug development platforms.
  • Diagnostics: Extractions may be able to be performed on site to facilitate neuropeptide identification in patients to tag them for specific neurological ailments. May need to be used in conjunction with MRI or PET scans for verification.

 

Advantages:

  • High resolution spectrometry allows for higher sensitivity and selectivity in peptide identification and study
  • Potentially increases the efficiency of the extraction process than what is currently available in the market

 

Licensing Manager:

Paul Eynott

PaulE@tla.arizona.edu

(520) 471-2687